Supplementary figure S6. Expectations regarding the new DMT by EDSS score subgroup

Figure S6a. Physicians' expectations by EDSS score subgroup[a]



EDSS 0-3.5	71.2	62.4	56.6	47.4	20.3	4.5	0.4
EDSS ≥ 4	69.3	59.4	72.3	37.6	17.8	5.0	0

	Patient number		
EDSS score subgroup	**0-3.5 N=468**	**≥ 4 N=101**	**Missing N=26**
Prevention of relapses	333	70	20
Prevention of new lesions	292	60	13
Effects on progression of disability	265	73	10
Good tolerability	222	38	14
Convenient application form	95	18	7
Less extensive pharmacovigilance monitoring	21	5	1
Convenient costs	2	0	0

Figure S6b. Patients' expectations by EDSS score subgroup[b]



EDSS 0-3.5	55.1	49.6	44.4	31.2	0.2
EDSS ≥ 4	44.6	59.4	49.5	28.7	0

	Patient number		
EDSS score subgroup	**0-3.5 N=468**	**≥ 4 N=101**	**Missing N=26**
Good tolerability	258	45	18
Effects on progression of disability	232	60	10
Good efficacy	208	50	7
Convenient application form	146	29	10
No data available	1	0	0

[a]Data were recorded using physician questionnaires. Up to three answers were possible. Answer options: relevance of drug characteristics with regard to prevention of relapses, prevention of new lesions, effects on progression of disability, good tolerability, less extensive pharmacovigilance monitoring, convenient application form, costs.
[b]Data were recorded using patient questionnaires. Up to two answers were possible. Answer options: relevance of drug characteristics with regard to good effectiveness, effects on progression of disability, good tolerability, convenient application form.

DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale.